Targeting activated mineralocorticoid receptor: Occam's razor revisited
نویسندگان
چکیده
منابع مشابه
Peroxisome Proliferator-Activated Receptor- and Receptor- Activators Prevent Cardiac Fibrosis in Mineralocorticoid-Dependent Hypertension
Peroxisome proliferator-activated receptor (PPAR) activation may prevent cardiac hypertrophy and inhibit production of endothelin-1 (ET-1), a hypertrophic agent. The aim of this in vivo study was to investigate the effects of PPAR activators on cardiac remodeling in DOCA-salt rats, a model overexpressing ET-1. Unilaterally nephrectomized 16-week-old Sprague-Dawley rats (Uni-Nx) were randomly di...
متن کاملThe Promiscuous Mineralocorticoid Receptor.
The article by Briet et al in this issue, “Aldosterone-induced vascular remodeling and endothelial dysfunction require functional angiotensin type 1a receptors,” represents a prodigious amount of work by the authors: it is not surprising that the first 3 are credited as having equally contributed. The authors build on previous in vitro studies, generously cited, on the interactions between mine...
متن کاملTargeting Revisited
Public spending programs aimed at alleviating poverty can either be broadly targeted at categories of spending or narrowly targeted at types of people. Each approach has benefits and costs to the poor. It is often claimed that narrow targeting of the poor will allow governments to reduce poverty more effectively and at lower cost. But narrow targeting often has hidden costs, and once these cost...
متن کامل30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
The cDNA of the mineralocorticoid receptor (MR) was cloned 30 years ago, in 1987. At that time, spirolactone, the first generation of synthetic steroid-based MR antagonists (MRAs), which was identified in preclinical in vivo models, had already been in clinical use for 30 years. Subsequent decades of research and development by Searle & Co., Ciba-Geigy, Roussel Uclaf and Schering AG toward iden...
متن کاملMineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.
C ardiac and renal diseases remain major challenges for healthcare systems in developed countries and commonly coexist, with a disorder in the heart or kidney often leading to secondary dysfunction or injury in the other organ. Indeed, the term cardiorenal syndrome has been introduced to describe the broad spectrum of disease involving both the heart and kidneys. 1 Aldosterone is a steroid horm...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Kidney International
سال: 2012
ISSN: 0085-2538
DOI: 10.1038/ki.2012.157